3 results
Primary: To assess the efficacy of treatment with 300 mg or 600 mg of intravenous (IV) zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily on time to clinical response. Secondary: reduction in viral load from nasopharyngeal swabs…
The main objective of this study is to assess effectiveness of the COVID-19 vaccinations, based on humoral (anti-coronavirus antibody) immunity, in GCA and PMR patients. Other objectives are assessing antigen-specific cellular (T-cell) immune…
The primary objective is to study protective antibody responses after SARS-CoV-2 vaccination in patients with pSS. Secondary objectives are monitoring of adverse events and disease activity after vaccination, studying the prognostic value of anti-…